e risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements, including market acceptance and demand for NxStage's products, growth in home and/or daily hemodialysis, unanticipated difficulties in achieving operational efficiencies and cost reductions, changes in reimbursement for home and daily hemodialysis, changes in the regulatory environment, changes in the historical purchasing patterns and preferences of our major customers, including DaVita Inc., and certain other factors that may affect future operating results and which are detailed in NxStage's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the period ended June 30, 2009.
In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.
Kristen K. Sheppard, Esq.
VP, Investor Relations
Non-GAAP Financial Measure
The Company discloses a certain non-GAAP financial measure to supplement the Company's consolidated financial statements presented on a GAAP basis. This non-GAAP measure is not in accordance with, or an alternative for, Page: 1 2 3 4 5 6 7 8 9 10 11 Related medicine technology :1
. NxStage(R) to Recognize Several Key Milestones at American Society of Nephrologys Renal Week 20072
. Boston Business Journal Names NxStage(R) Medical Third Fastest Growing Company in Massachusetts3
. NxStage(R) to Report Third Quarter 2009 Financial Results4
. NxStage(R) Reports Significant Interim FREEDOM Study Results5
. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound6
. Spherix Reports Second Quarter Earnings7
. Tapestry Reports Second Quarter 2007 Results8
. Callisto Reports on Second-Quarter 2007 Milestones9
. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.10
. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs11
. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress